The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global PD-1 Inhibitor Market Research Report 2025
Synopsis
The global PD-1 Inhibitor market was valued at US$ 31410 million in 2023 and is anticipated to reach US$ 43130 million by 2030, witnessing a CAGR of 4.7% during the forecast period 2024-2030.
North American market for PD-1 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for PD-1 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for PD-1 Inhibitor in Melanoma is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of PD-1 Inhibitor include Merck, Novartis, Onxeo, Sumitomo Dainippon Pharma, Taiwan Liposome Company, Tiziana Life Sciences, Genentech (Roche), AstraZeneca and Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for PD-1 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 Inhibitor.
Report Scope
The PD-1 Inhibitor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PD-1 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-1 Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Novartis
Onxeo
Sumitomo Dainippon Pharma
Taiwan Liposome Company
Tiziana Life Sciences
Genentech (Roche)
AstraZeneca
Pfizer
Segment by Type
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab
Avelumab
Others
Segment by Application
Melanoma
Non-small Cell Lung Cancer (NSCLC)
Urothelial Carcinoma
Classical Hodgkin Lymphoma
Renal Cell Carcinoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-1 Inhibitor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global PD-1 Inhibitor market was valued at US$ 31410 million in 2023 and is anticipated to reach US$ 43130 million by 2030, witnessing a CAGR of 4.7% during the forecast period 2024-2030.
North American market for PD-1 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for PD-1 Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for PD-1 Inhibitor in Melanoma is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of PD-1 Inhibitor include Merck, Novartis, Onxeo, Sumitomo Dainippon Pharma, Taiwan Liposome Company, Tiziana Life Sciences, Genentech (Roche), AstraZeneca and Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for PD-1 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 Inhibitor.
Report Scope
The PD-1 Inhibitor market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PD-1 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-1 Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Novartis
Onxeo
Sumitomo Dainippon Pharma
Taiwan Liposome Company
Tiziana Life Sciences
Genentech (Roche)
AstraZeneca
Pfizer
Segment by Type
Pembrolizumab
Nivolumab
Atezolizumab
Durvalumab
Avelumab
Others
Segment by Application
Melanoma
Non-small Cell Lung Cancer (NSCLC)
Urothelial Carcinoma
Classical Hodgkin Lymphoma
Renal Cell Carcinoma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-1 Inhibitor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PD-1 Inhibitor Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pembrolizumab
1.2.3 Nivolumab
1.2.4 Atezolizumab
1.2.5 Durvalumab
1.2.6 Avelumab
1.2.7 Others
1.3 Market by Application
1.3.1 Global PD-1 Inhibitor Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Melanoma
1.3.3 Non-small Cell Lung Cancer (NSCLC)
1.3.4 Urothelial Carcinoma
1.3.5 Classical Hodgkin Lymphoma
1.3.6 Renal Cell Carcinoma
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global PD-1 Inhibitor Market Perspective (2019-2030)
2.2 PD-1 Inhibitor Growth Trends by Region
2.2.1 Global PD-1 Inhibitor Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 PD-1 Inhibitor Historic Market Size by Region (2019-2024)
2.2.3 PD-1 Inhibitor Forecasted Market Size by Region (2025-2030)
2.3 PD-1 Inhibitor Market Dynamics
2.3.1 PD-1 Inhibitor Industry Trends
2.3.2 PD-1 Inhibitor Market Drivers
2.3.3 PD-1 Inhibitor Market Challenges
2.3.4 PD-1 Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top PD-1 Inhibitor Players by Revenue
3.1.1 Global Top PD-1 Inhibitor Players by Revenue (2019-2024)
3.1.2 Global PD-1 Inhibitor Revenue Market Share by Players (2019-2024)
3.2 Global PD-1 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by PD-1 Inhibitor Revenue
3.4 Global PD-1 Inhibitor Market Concentration Ratio
3.4.1 Global PD-1 Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PD-1 Inhibitor Revenue in 2023
3.5 PD-1 Inhibitor Key Players Head office and Area Served
3.6 Key Players PD-1 Inhibitor Product Solution and Service
3.7 Date of Enter into PD-1 Inhibitor Market
3.8 Mergers & Acquisitions, Expansion Plans
4 PD-1 Inhibitor Breakdown Data by Type
4.1 Global PD-1 Inhibitor Historic Market Size by Type (2019-2024)
4.2 Global PD-1 Inhibitor Forecasted Market Size by Type (2025-2030)
5 PD-1 Inhibitor Breakdown Data by Application
5.1 Global PD-1 Inhibitor Historic Market Size by Application (2019-2024)
5.2 Global PD-1 Inhibitor Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America PD-1 Inhibitor Market Size (2019-2030)
6.2 North America PD-1 Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America PD-1 Inhibitor Market Size by Country (2019-2024)
6.4 North America PD-1 Inhibitor Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PD-1 Inhibitor Market Size (2019-2030)
7.2 Europe PD-1 Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe PD-1 Inhibitor Market Size by Country (2019-2024)
7.4 Europe PD-1 Inhibitor Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific PD-1 Inhibitor Market Size (2019-2030)
8.2 Asia-Pacific PD-1 Inhibitor Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific PD-1 Inhibitor Market Size by Region (2019-2024)
8.4 Asia-Pacific PD-1 Inhibitor Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America PD-1 Inhibitor Market Size (2019-2030)
9.2 Latin America PD-1 Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America PD-1 Inhibitor Market Size by Country (2019-2024)
9.4 Latin America PD-1 Inhibitor Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PD-1 Inhibitor Market Size (2019-2030)
10.2 Middle East & Africa PD-1 Inhibitor Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa PD-1 Inhibitor Market Size by Country (2019-2024)
10.4 Middle East & Africa PD-1 Inhibitor Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck PD-1 Inhibitor Introduction
11.1.4 Merck Revenue in PD-1 Inhibitor Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis PD-1 Inhibitor Introduction
11.2.4 Novartis Revenue in PD-1 Inhibitor Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Onxeo
11.3.1 Onxeo Company Detail
11.3.2 Onxeo Business Overview
11.3.3 Onxeo PD-1 Inhibitor Introduction
11.3.4 Onxeo Revenue in PD-1 Inhibitor Business (2019-2024)
11.3.5 Onxeo Recent Development
11.4 Sumitomo Dainippon Pharma
11.4.1 Sumitomo Dainippon Pharma Company Detail
11.4.2 Sumitomo Dainippon Pharma Business Overview
11.4.3 Sumitomo Dainippon Pharma PD-1 Inhibitor Introduction
11.4.4 Sumitomo Dainippon Pharma Revenue in PD-1 Inhibitor Business (2019-2024)
11.4.5 Sumitomo Dainippon Pharma Recent Development
11.5 Taiwan Liposome Company
11.5.1 Taiwan Liposome Company Company Detail
11.5.2 Taiwan Liposome Company Business Overview
11.5.3 Taiwan Liposome Company PD-1 Inhibitor Introduction
11.5.4 Taiwan Liposome Company Revenue in PD-1 Inhibitor Business (2019-2024)
11.5.5 Taiwan Liposome Company Recent Development
11.6 Tiziana Life Sciences
11.6.1 Tiziana Life Sciences Company Detail
11.6.2 Tiziana Life Sciences Business Overview
11.6.3 Tiziana Life Sciences PD-1 Inhibitor Introduction
11.6.4 Tiziana Life Sciences Revenue in PD-1 Inhibitor Business (2019-2024)
11.6.5 Tiziana Life Sciences Recent Development
11.7 Genentech (Roche)
11.7.1 Genentech (Roche) Company Detail
11.7.2 Genentech (Roche) Business Overview
11.7.3 Genentech (Roche) PD-1 Inhibitor Introduction
11.7.4 Genentech (Roche) Revenue in PD-1 Inhibitor Business (2019-2024)
11.7.5 Genentech (Roche) Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Detail
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca PD-1 Inhibitor Introduction
11.8.4 AstraZeneca Revenue in PD-1 Inhibitor Business (2019-2024)
11.8.5 AstraZeneca Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer PD-1 Inhibitor Introduction
11.9.4 Pfizer Revenue in PD-1 Inhibitor Business (2019-2024)
11.9.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global PD-1 Inhibitor Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Pembrolizumab
Table 3. Key Players of Nivolumab
Table 4. Key Players of Atezolizumab
Table 5. Key Players of Durvalumab
Table 6. Key Players of Avelumab
Table 7. Key Players of Others
Table 8. Global PD-1 Inhibitor Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global PD-1 Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global PD-1 Inhibitor Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global PD-1 Inhibitor Market Share by Region (2019-2024)
Table 12. Global PD-1 Inhibitor Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global PD-1 Inhibitor Market Share by Region (2025-2030)
Table 14. PD-1 Inhibitor Market Trends
Table 15. PD-1 Inhibitor Market Drivers
Table 16. PD-1 Inhibitor Market Challenges
Table 17. PD-1 Inhibitor Market Restraints
Table 18. Global PD-1 Inhibitor Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global PD-1 Inhibitor Market Share by Players (2019-2024)
Table 20. Global Top PD-1 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 Inhibitor as of 2023)
Table 21. Ranking of Global Top PD-1 Inhibitor Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by PD-1 Inhibitor Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players PD-1 Inhibitor Product Solution and Service
Table 25. Date of Enter into PD-1 Inhibitor Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global PD-1 Inhibitor Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global PD-1 Inhibitor Revenue Market Share by Type (2019-2024)
Table 29. Global PD-1 Inhibitor Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global PD-1 Inhibitor Revenue Market Share by Type (2025-2030)
Table 31. Global PD-1 Inhibitor Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global PD-1 Inhibitor Revenue Market Share by Application (2019-2024)
Table 33. Global PD-1 Inhibitor Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global PD-1 Inhibitor Revenue Market Share by Application (2025-2030)
Table 35. North America PD-1 Inhibitor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America PD-1 Inhibitor Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America PD-1 Inhibitor Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe PD-1 Inhibitor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe PD-1 Inhibitor Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe PD-1 Inhibitor Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific PD-1 Inhibitor Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific PD-1 Inhibitor Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific PD-1 Inhibitor Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America PD-1 Inhibitor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America PD-1 Inhibitor Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America PD-1 Inhibitor Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa PD-1 Inhibitor Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa PD-1 Inhibitor Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa PD-1 Inhibitor Market Size by Country (2025-2030) & (US$ Million)
Table 50. Merck Company Detail
Table 51. Merck Business Overview
Table 52. Merck PD-1 Inhibitor Product
Table 53. Merck Revenue in PD-1 Inhibitor Business (2019-2024) & (US$ Million)
Table 54. Merck Recent Development
Table 55. Novartis Company Detail
Table 56. Novartis Business Overview
Table 57. Novartis PD-1 Inhibitor Product
Table 58. Novartis Revenue in PD-1 Inhibitor Business (2019-2024) & (US$ Million)
Table 59. Novartis Recent Development
Table 60. Onxeo Company Detail
Table 61. Onxeo Business Overview
Table 62. Onxeo PD-1 Inhibitor Product
Table 63. Onxeo Revenue in PD-1 Inhibitor Business (2019-2024) & (US$ Million)
Table 64. Onxeo Recent Development
Table 65. Sumitomo Dainippon Pharma Company Detail
Table 66. Sumitomo Dainippon Pharma Business Overview
Table 67. Sumitomo Dainippon Pharma PD-1 Inhibitor Product
Table 68. Sumitomo Dainippon Pharma Revenue in PD-1 Inhibitor Business (2019-2024) & (US$ Million)
Table 69. Sumitomo Dainippon Pharma Recent Development
Table 70. Taiwan Liposome Company Company Detail
Table 71. Taiwan Liposome Company Business Overview
Table 72. Taiwan Liposome Company PD-1 Inhibitor Product
Table 73. Taiwan Liposome Company Revenue in PD-1 Inhibitor Business (2019-2024) & (US$ Million)
Table 74. Taiwan Liposome Company Recent Development
Table 75. Tiziana Life Sciences Company Detail
Table 76. Tiziana Life Sciences Business Overview
Table 77. Tiziana Life Sciences PD-1 Inhibitor Product
Table 78. Tiziana Life Sciences Revenue in PD-1 Inhibitor Business (2019-2024) & (US$ Million)
Table 79. Tiziana Life Sciences Recent Development
Table 80. Genentech (Roche) Company Detail
Table 81. Genentech (Roche) Business Overview
Table 82. Genentech (Roche) PD-1 Inhibitor Product
Table 83. Genentech (Roche) Revenue in PD-1 Inhibitor Business (2019-2024) & (US$ Million)
Table 84. Genentech (Roche) Recent Development
Table 85. AstraZeneca Company Detail
Table 86. AstraZeneca Business Overview
Table 87. AstraZeneca PD-1 Inhibitor Product
Table 88. AstraZeneca Revenue in PD-1 Inhibitor Business (2019-2024) & (US$ Million)
Table 89. AstraZeneca Recent Development
Table 90. Pfizer Company Detail
Table 91. Pfizer Business Overview
Table 92. Pfizer PD-1 Inhibitor Product
Table 93. Pfizer Revenue in PD-1 Inhibitor Business (2019-2024) & (US$ Million)
Table 94. Pfizer Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
List of Figures
Figure 1. Global PD-1 Inhibitor Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global PD-1 Inhibitor Market Share by Type: 2023 VS 2030
Figure 3. Pembrolizumab Features
Figure 4. Nivolumab Features
Figure 5. Atezolizumab Features
Figure 6. Durvalumab Features
Figure 7. Avelumab Features
Figure 8. Others Features
Figure 9. Global PD-1 Inhibitor Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global PD-1 Inhibitor Market Share by Application: 2023 VS 2030
Figure 11. Melanoma Case Studies
Figure 12. Non-small Cell Lung Cancer (NSCLC) Case Studies
Figure 13. Urothelial Carcinoma Case Studies
Figure 14. Classical Hodgkin Lymphoma Case Studies
Figure 15. Renal Cell Carcinoma Case Studies
Figure 16. Others Case Studies
Figure 17. PD-1 Inhibitor Report Years Considered
Figure 18. Global PD-1 Inhibitor Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 19. Global PD-1 Inhibitor Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 20. Global PD-1 Inhibitor Market Share by Region: 2023 VS 2030
Figure 21. Global PD-1 Inhibitor Market Share by Players in 2023
Figure 22. Global Top PD-1 Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 Inhibitor as of 2023)
Figure 23. The Top 10 and 5 Players Market Share by PD-1 Inhibitor Revenue in 2023
Figure 24. North America PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America PD-1 Inhibitor Market Share by Country (2019-2030)
Figure 26. United States PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Canada PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Europe PD-1 Inhibitor Market Share by Country (2019-2030)
Figure 30. Germany PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. France PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. U.K. PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Italy PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Russia PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Nordic Countries PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Asia-Pacific PD-1 Inhibitor Market Share by Region (2019-2030)
Figure 38. China PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Japan PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. South Korea PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Southeast Asia PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. India PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Australia PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Latin America PD-1 Inhibitor Market Share by Country (2019-2030)
Figure 46. Mexico PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Brazil PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa PD-1 Inhibitor Market Share by Country (2019-2030)
Figure 50. Turkey PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia PD-1 Inhibitor Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Merck Revenue Growth Rate in PD-1 Inhibitor Business (2019-2024)
Figure 53. Novartis Revenue Growth Rate in PD-1 Inhibitor Business (2019-2024)
Figure 54. Onxeo Revenue Growth Rate in PD-1 Inhibitor Business (2019-2024)
Figure 55. Sumitomo Dainippon Pharma Revenue Growth Rate in PD-1 Inhibitor Business (2019-2024)
Figure 56. Taiwan Liposome Company Revenue Growth Rate in PD-1 Inhibitor Business (2019-2024)
Figure 57. Tiziana Life Sciences Revenue Growth Rate in PD-1 Inhibitor Business (2019-2024)
Figure 58. Genentech (Roche) Revenue Growth Rate in PD-1 Inhibitor Business (2019-2024)
Figure 59. AstraZeneca Revenue Growth Rate in PD-1 Inhibitor Business (2019-2024)
Figure 60. Pfizer Revenue Growth Rate in PD-1 Inhibitor Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
